LLY

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2002, for Eli Lilly and Company, a pharmaceutical company incorporated in Indiana. The company operates primarily in one significant business segment: pharmaceutical products for humans, with a non-material animal health segment. The filing includes unaudited consolidated financial statements and management's discussion and analysis.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Net sales decreased 3% in the third quarter and 7% for the nine-month period compared to 2001. This decline was primarily driven by a 58% drop in fluoxetine (Prozac) sales due to generic competition, partially offset by growth in Zyprexa, Humalog, Evista, and Gemzar.
• Profitability: Reported net income increased 20% in the third quarter but decreased 11% for the nine-month period. Adjusted for unusual items, net income increased 2% in the quarter but declined 14% for the nine-month period.
• Expenses: Operating expenses decreased 7% in the quarter and 2% for the nine months. Research and development spending declined due to lower late-stage clinical trial costs. Marketing expenses decreased due to lower Prozac promotional costs.
• Debt: Total debt increased by $1.83 billion from December 31, 2001, due to the issuance of new notes and bonds to manage liquidity and interest rates.
• Unusual Items: The company recorded an $84.0 million charge for acquired in-process research and development (Amylin collaboration) in Q3 2002. In Q3 2001, the company recorded $121.4 million in asset impairments and a $16.6 million net extraordinary charge for debt repurchase.

Guidance, Outlook, and Risks

• 2002 Guidance: Management expects a slight decline in full-year 2002 sales, with Q4 sales returning to mid-single-digit growth. Full-year 2002 diluted earnings per share (excluding unusual items) are expected to be in the range of $2.55 to $2.57, a reduction from prior guidance of $2.60 to $2.62. Q4 2002 EPS is expected to be $0.68 to $0.70 (excluding unusual items).
• 2003 Outlook: Management aims to deliver earnings growth in 2003, contingent on the resolution of manufacturing issues and the timing of new product launches.
• Manufacturing Risks: The FDA issued a warning letter regarding Good Manufacturing Practices (cGMP) at Indianapolis facilities. Resolution of these issues is critical for the approval of Zyprexa IntraMuscular, Forteo, and Cymbalta. Failure to resolve could lead to production interruptions or approval delays.
• Legal Risks: Significant patent litigation is ongoing regarding Zyprexa (Zenith, Reddy, Teva) and Evista (Barr). An unfavorable outcome could materially impact results. Additionally, Pfizer has sued regarding Cialis patent infringement.
• Pricing Pressures: The company faces increasing pricing pressures in the U.S. due to Medicare/Medicaid reform debates and state-level cost-reduction measures.

Investor Verification Checklist

• Verify the status of FDA inspections and the timeline for resolving cGMP issues at Indianapolis facilities, as this impacts the launch of Cymbalta, Forteo, and Zyprexa IntraMuscular.
• Monitor the progress of patent litigation concerning Zyprexa and Evista, as a loss could significantly reduce future revenue streams.
• Track the sales performance of growth drivers (Zyprexa, Humalog, Gemzar, Evista) to ensure they continue to offset the decline in legacy products like Prozac.
• Review the company's ability to meet the revised 2002 EPS guidance of $2.55–$2.57, considering the impact of lower sales from ReoPro and anti-infectives.
• Assess the impact of the $84.0 million in-process R&D charge and future collaboration expenses on operating margins.